Locally advanced pancreatic adenocarcinoma: Where are we and where are we going?

Journal of the Pancreas

Volumn 12, Issue 2, 2011, Pages 101-105

  Chang, Bryan W ^a   Saif, Muhammad Wasif ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

Bevacizumab; Erlotinib; Fluorouracil; Gemcitabine; Oxaliplatin; Pancreatic neoplasms; Radiother

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GOLNERMINOGENE PRADENOVEC; IRINOTECAN; NELFINAVIR; OXALIPLATIN; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SORAFENIB; TIPIFARNIB; VASCULOTROPIN;

ACUTE TOXICITY; ADVANCED CANCER; ANOREXIA; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; DRUG DOSE ESCALATION; DRUG EFFICACY; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HUMAN; LUNG TOXICITY; NEUTROPENIA; PANCREAS ADENOCARCINOMA;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; PANCREATIC NEOPLASMS; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 79952777607     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Loehrer PJ, Powell ME, Cardenes HR, et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: e4201 [abstract]. J Clin Oncol 26, a4506 (2008).
2. Heinemann V, Labianca R, Hinke A, et al. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol. 2007 Oct; 18(10):1652-1659. Epub 2007 Jul 28.
3. Huguet F, André T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007 Jan 20;25(3):326-331.
4. Bloomston M, Marsh C, Walker J, et al. Phase I trial of genemediated cytotoxic immunotherapy in combination with chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2011; 29(Suppl. 4):Abstract 195.
5. Czito BG, Willett C, Kennedy-Newton P, et al. A phase I study of erlotinib, bevacizumab, and external beam radiation therapy (RT) for patients with localized pancreatic carcinoma (PC). J Clin Oncol 2011; 29(Suppl. 4): Abstract 281.
6. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). J Clin Oncol 2005; 23(16S part 1). Abstract No: 1.
7. Chang, K. J., Fisher W, Kenady D, et al. Multicenter randomized controlled phase III clinical trial using TNFerade (TNF) with chemoradiation (CRT) in patients with locally advanced pancreatic cancer (LAPC): Interim analysis (IA) of overall survival (OS) [abstract]. J Clin Oncol 2009; 27, Abstract 4605.
8. Sudo K, Yamaguchi T, Ishihara T, Nakamura K, Hara T, Denda T, Tawada K, Imagumbai T, Araki H, Sakai M, Hatano K, Kawakami H, Uno T, Ito H, Yokosuka O. Phase II Study of Oral S-1and Concurrent Radiotherapy in Patients with Unresectable Locally Advanced Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2010 Jun 2.
9. Crane CH, Winter K, Regine WF, et al. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol 2009 Sep 1;27(25):4096-4102.
10. Anderson S, Cardenes HR, Akisik F, et al. Phase I study of sorafenib (S) with gemcitabine (G)-based radiotherapy (G-RT) in patients (pts) with locally advanced unresectable pancreatic adenocarcinoma (LAUPC). J Clin Oncol 2010: 28:15s, (suppl; abstr 4139).
11. Rich T, Harris J, Abrams R, et al. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectablepancreatic cancer: RTOG-98-12. Am J Clin Oncol 2004 Feb;27(1):51-56.
12. Brunner TB, Geiger M, Grabenbauer GG, et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir andchemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2008 Jun 1;26(16):2699-2706.
13. Duffy A, Kortmansky J, Schwartz GK, et al. A phase I study of erlotinib in combination with gemcitabine and radiation in locallyadvanced, non-operable pancreatic adenocarcinoma. Ann Oncol 2008 Jan;19(1): 86-91.
14. Crane CH, Varadhachary GR, Javle MM, et al. Multiinstitutional phase II trial of induction cetuximab, gemcitabine, andoxaliplatin, followed by radiotherapy with concurrent capecitabine, and cetuximab, for locally advanced pancreatic adenocarcinoma(LAPC). J Clin Oncol 2010; ASCO Gastrointestinal Cancers Symposium. Abstract No. 132.
15. Prakash C, Huang S, Vallabhaneni G, et al. Mechanisms of Enhanced Radiation Response following Epidermal Growth FactorReceptor Signaling Inhibition by Erlotinib (Tarceva). Cancer Res 65: 3328-3335, 2005.
16. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases theantitumor effects of ionizing radiation. Cancer Res 59:3374-3378,1999.
17. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical Wound Healing Complications in Metastatic Colorectal CancerPatients Treated with Bevacizumab. J Surg Oncol 2005; 91:173-180.
18. Huang J, Robertson JM, Margolis JH, et al. Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreatic cancer. J Clin Oncol 2011; 29(Suppl. 4):Abstract 287.
19. Lin C, Kos BM, Sasson AR, et al. A phase II study of neoadjuvant gemcitabine/5-fluorouracil followed by 5-fluorouracil/oxaliplatin concurrent with radiation in patients with locally advanced pancreatic cancer. J Clin Oncol 2011; 29(Suppl. 4):Abstract 259.
20. Ioka T, Fukutake N, Ikezawa K, et al. Concurrent chemoradiotherapy with gemcitabine and S-1 for unresectable locally advanced pancreatic adenocarcinoma: A phase I study. J Clin Oncol 2011; 29(Suppl. 4):Abstract 305.
21. Kim EJ, Ben-Josef E, Griffith A, et al. Phase II trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation (RT) in patients with resectable (R) or borderline resectable (BR) pancreatic cancer. J Clin Oncol 2011; 29(Suppl. 4):Abstract 239.
22. Li CP, Chao Y, Chi KH,et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys. 2003 Sep 1; 57(1):98-104.
23. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 19(9): 1592-1599, 2008.
24. Ioka, T., Nakamura, S., Nishiyama, K. A randomized phase II study of gemcitabine 1000 mg/m2 and concurrent radiotherapy comparing gemcitabine alone for unresectable locally advanced pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2010; 78(3, Supplement):S102.
25. E. Ben-Josef, K. Griffith, I. R. Francis et al. Phase I radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer. J Clin Oncol 2009; 27:15s (suppl; abstr 4602).
26. Murphy JD, Adusumilli S, Griffith KA, et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int. J. Rad Oncol Biol Phys, Vol. 68, No. 3, pp. 801-808, 2008.
27. Ishii H, Okada S, Tokuuye K, et al. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer. 1997 Apr 15; 79(8):1516-1520.
28. André T, Balosso J, Louvet C, et al. Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study. Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):903-911.
29. Kornek GV, Schratter-Sehn A, Marczell A, et al. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin. Br J Cancer. 2000 Jan; 82(1):98-103.
30. Boz G, De Paoli A, Innocente R, et al. Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma. Int J Radiat Oncol Biol Phys. 2001 Nov 1; 51(3):736-740.
31. Crane CH, Antolak JA, Rosen II et al. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer 30(3):123-32, 2001.
32. Small W, Jr, Berlin J, Freedman GM, et al. Full-Dose Gemcitabine With Concurrent Radiation Therapy in Patients With Nonmetastatic Pancreatic Cancer: A Multicenter Phase II Trial. J Clin Oncol 26(6): 9427-7, 2008.
33. Hosein PJ, Kawamura C, Macintyre J, et al. Pilot study of neoadjuvant FOLFIRINOX in unresectable locally advanced (LA) pancreatic carcinoma (PC). J Clin Oncol 2011; 29(Suppl. 4):Abstract 324.
34. Tanaka T, Nishiofuku H, Sho M, et al. Phase I/II study of arterial infusion with 5-fluorouracil combined with systemic gemcitabine for unresectable pancreatic cancer. J Clin Oncol 2011; 29(Suppl. 4): Abstract 307.
35. Conroy T, Desseigne F, Ychou M et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol 2010; 28:15s,(suppl; abstr 4010).
36. Krishnan S, Rana V, Janjan NA, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 2007 Jul 1;110(1): 47-55.